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Role of dialysable solutes in the mediation of uremic encephalopathy in
the rat. This study addresses mechanisms of the clinical, encephalo-
pathic uremic illness and its suppression by dialysis. Renoprival rats
were treated with peritoneal dialysis (8 exchanges per day, 30 mm
dwell), or untreated (attrition group), and their EEG's were automati-
cally sampled overnight and subjected to power spectrum analysis as an
index of encephalopathy. As in man the background rhythm of the
quantified EEG (Q.EEG) in the attrition group slowed with time as
extracellular fluid composition became increasingly abnormal; these
changes were normalized by therapeutic dialysis (TD) using standard,
commercial diálysate. However, Q.EEG slowing was only partially
normalized by solute-specific dialysis using 'mock uremic dialysate"
(M-UD), prepared from laboratory chemicals to equal plasma concen-
trations in preterminal uremic rats of urea, creatinine, potassium,
phosphorus, calcium, magnesium, bicarbonate, sodium, and chloride.
When only phosphate was added to TD, the Q.EEG slowed to the same
level achieved after M-UD. We conclude that uremic encephalopathy in
this model is produced by an unknown neurotoxin and augmented by
one or more of the M-UD solutes, phosphate being a likely candidate.
To localize the encephalopathic effect, regional brain glucose uptake
was estimated in 20 discrete brain areas. Significance of reduced uptake
in three areas is discussed.
These studies address two fundamental, unanswered ques-
tions: (1) How does renal failure make patients sick? and (2)
How does dialysis reverse that clinical illness? While the
significant success of dialysis procedures makes these questions
less clinically urgent, both the empirically described illness
("clinical uremia") and its response to empirical treatment
(dialysis) deserve a rational, mechanistic explanation.
The clinical illness of severe uremia is most cogently typified
as an encephalopathy, an "illness behavior" represented by
derangement of psychic function (affect, cognition and, termi-
nally, vegetative function) at all levels of cerebral organization
[1—7]. In both animals and man, this syndrome of uremic
encephalopathy is indexed by certain neurobehavioral mea-
sures [3] and by reproducible and characteristic changes in the
background rhythm of the quantitative electroencephalogram
(Q.EEG). These have been described as "slowing", or the loss
of high frequency activity [8—131. The syndrome and its elec-
troencephalographic derangements are ameliorated by both
peritoneal and hemodialysis [3, 141. From this we infer that the
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proximate neurotoxic factor is either itself dialysable (the
dialysable neurotoxin hypothesis of Schreiner and Maher [15])
or that its effects indirectly respond to dialytic removal of some
other solute (the "trade-off" hypothesis of Bricker [161). Clin-
ically, the degree of uremia is also indexed by the extent of
derangement of the levels of certain commonly measured
extracellular fluid (ECF) solutes, notably urea, creatinine,
calcium, phosphorus, potassium and bicarbonate. These levels
change due to the ui-ernie patient's reduced renal excretory
capacity and, together with the symptomatology of uremic
encephalopathy, their levels are restored toward normal by
dialysis. The extent to which any of these moieties contribute to
uremic encephalopathy is, however, unknown.
The pathogenesis of uremie encephalopathy has been ex-
plored by a number of authors in terms of the electrical and
metabolic indices of brain function. In the rat, Van den Noort et
al [17] found that creatinine, phosphate, ATP and glucose
content were increased but that there were corresponding
decreases in creatinine, AMP, ADP and lactate. Total brain
adenine nucleotide content was normal to low. The work of
Mahoney, Sarnaeki and Arieff [181 on the ui-ernie dog would
suggest that energy charge in the ui-ernie brain is unchanged
while substrate utilization is reduced.
The present investigation sought to examine the encephalo-
pathic effect of uremia in a nephrectomized rat model amenable
to chronic conscious ambulatory Q.EEG recording and perito-
neal dialysis (PD). Our purpose was to investigate the correla-
tion, if any, between encephalopathic changes in the EEG and
the abnormal concentration of commonly measured ECF sol-
utes that occur in renal failure and are modified by dialysis. In
addition, because glucose uptake and metabolism is critical for
brain function we postulated that the observed neurobehavioral
deficits and their amelioration by dialysis should be reflected in
differences in quantitative regional cerebral glucose uptake
(rCGlu). With this model, the "dialysable neurotoxin" hypoth-
esis was tested insofar as it relates to the combined influences of
urea, creatinine, calcium, phosphorus and potassium, while
sodium and chloride and presumably bicarbonate remained
essentially unchanged. The method has previously been suc-
cessfully used to maintain conscious ambulatory renoprival
animals for up to 13.5 days and to determine the relationship
between degree of uremia and degree of Q.EEG slowing in this
species [14, 191. It was hypothesized that dialysate formulated
to contain "uremic" levels of these solutes—so as to prevent
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Fig. 1. Typical compressed spectral arrays of the Q.EEG measured
from a control, sham nephrectomized (Sham Nx, upper frame) and a
uremic, nephrectomized (Attrition, lower frame) animal. The frequency
boundaries (Hz) are shown for the delta, theta, alpha and beta bands.
Ordinate indicates power. The arrays are composed of 25 four second
epochs. The figure illustrates the phenomenon whereby the theta:alpha
ratio (TAR) increases as the power distribution shifts to the lower
frequencies; that is, as the background rhythm slows.
their dialytic removal from the renoprival rat's extracellular
fluid (ECF)—would maintain orexacerbate the encephalopathic
syndrome if one or more of them contributed to the neurotoxic
effect. Finally, the model was employed in a single, initial
example of single- solute-specific dialysis in which Q.EEG
responses were recorded when dialysate levels of phosphate
only were elevated to "uremic" levels.
Methods
Animals
There were fifty-five male Sprague-Dawley rats (Sasco Lab-
oratories, 250 g) used in these studies. Animal housing and
experimental facilities employed identical temperature and hu-
midity control with 12 hour light-dark rhythm. Animals were
acclimated for one week prior to surgical implantation of
chronic extradural silver ball EEG electrodes. Electrode im-
plantation was performed using the method of Lipman and
Harshman [20]. Briefly, monopolar electrodes were chronically
emplaced through burr holes in the skull bilaterally over frontal
and occipitoparietal cortices, a fifth, reference, electrode being
embedded in the bone of the nasion. The electrodes were
connected to a plug permanently mounted to the animal's skull.
Fourteen days were permitted to elapse to ensure proper
healing. Quantitative electroencephalographic (Q.EEG) mea-
surements were then made, sampling for 100 seconds every two
hours from groups of ten rats at a time for one week, using an
automated procedure we have previously described [21, 22].
Slowing of the dominant frequencies due to encephalopathy
was therefore indexed in these Q.EEG measurements by deriv-
ing the theta:alpha ratio (TAR) which is the ratio of powers
(p.V2) in theta and alpha bands (Power 3 to 7 Hz/Power 7 to 13
Hz; Fig. 1). Eight 100-second Q.EEG measurements were
obtained each night, the TAR was derived from each measure-
ment and these values averaged over the entire measuring
period (17:00 hr to 07:00 hr) for each rat. A minimum of three
nights of Q.EEG measurement were chosen from those ob-
tamed during the control, pre-nephrectomy, stage of the study,
and the average TAR values were then computed over these
three nights for each animal.
The animals were singly caged in clear acrylic observation
chambers and their electrodes attached by light, flexible
shielded cables to a digital switch box which sequentially
selected the individual rat whose signal was to be measured by
the EEG machine, from the group of ten connected. Selection
was made by a software generated control word sent from the
parallel port of a microcomputer (IBM PC/XT) which also
received and processed the signal. The selected rat's EEG
signal passed through the switch box to the EEG machine
producing a paper record. The amplified signal was additionally
sent to an analog-to-digital converter (Tecmar DT5712) where
the digitized signal was read into the IBM PCIXT computer, and
stored on the hard disk of the system. The system was also
equipped with a digital tape backup unit (Irwin Magnetics) for
permanent archiving of data. Following an EEG recording
session the data were displayed on a monochrome monitor and,
where required, a hard copy was produced on the attached
dot-matrix printer (Epson). Data management was accom-
plished on a remote mainframe computer (VU VAX 8800)
accessed by modem.
Surgical
After control Q.EEG recordings had been made, all animals
were surgically prepared for dialysis. The method of surgical
implantation of the peritoneal dialysis catheter guide is de-
scribed more fully elsewhere [23]. In use, a sterile peritoneal
dialysis (PD) catheter was inserted through a chronically im-
planted guide to rest intraperitoneally. Through this catheter
sterile dialysis fluid was instilled and withdrawn. In our prelim-
inary studies we found that a 60 minute equilibration with
therapeutic dialysate (Table 2) gave equilibrated peritoneal
dialysate solute (EPD solute) concentrations which approxi-
mate those measured from the uremic rat's serum (Table 1).
Such measurements, therefore, were made twice daily at 07:00
hours and 14:00 hours in lieu of blood sampling. Dialysate
volumes were restricted to 20 ml to minimize solute removal
from body stores. In those animals subjected to PD for control
of uremia, eight exchanges (each of 30 mm dwell time) were
conducted per day per rat, using 30 to 35 ml volumes (7.5% of
body weight [14, 24]). At the end of the dwell time, dialysate
urea levels were 75% equilibrated with serum. Bilateral ne-
phrectomy in those animals rendered uremic was performed
using a ventral approach, with omentectomy to prevent occlu-
sion of the PD catheter by omentum. Surgically prepared
animals were then assigned to the following groups and treated
according to the protocol illustrated in Figure 2.
Treatment groups
Animals of the Attrition Group (N = 10) were subjected to
jugular vein catheter implantation, bilateral nephrectomy and
omentectomy. These animals were not dialyzed except insofar
as EPD samples were taken twice daily. The Therapeutic
Dialysis Group (TD,N = 25), was treated as above except that
eight exchanges of peritoneal dialysis (30 ml vol, 30 mm dwell
time) were conducted using a commercial therapeutic dialysate
(Table 2) between 08:00 hours and 14:00 hours each day,
commencing 24 hours after nephrectomy. The Mock-Uremic
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Table 1. Equivalence of serum and equilibrated peritoneal dialysate chemistries in nephrectomized animals (N = 10)
Sample
Urea Cr Ca P Na K Cl
,ng/dl mEqiliter mM/liter
Blood 262 4.45 8.83 16.4 134 10.87 97.5 10.0
Dialysate
Ratio:
Blood
241
0.91
4.15
0.91
8.3
0.94
13.5
0.83
131
0.97
10.17
0.99
96.5
0.99
10.5
1.0
Table 2. Solute compositions of therapeutic and special dialysate
solutions; Mock uremic dialysate (M-UD), containing several solutes
at uremic concentration and phosphate-UD (P-UD) containing only
phosphorus at uremic concentration
Solute
Concentration
PD fluid
Therapeutic
dialysatea
Uremic dialysates
M-UD P-UD
Na mEqiliter
K mEqlliter
P1mg/dl
Ca mg/d!
Mg mEqiliter
Cl mEq/liter
HCO3 mEqiliter
Lactate mEqiliter
Gluconate mg/dl
Creatinine mg/dl
Urea mg/dl
Glucose mg/dl
132
0
0
7.0
1.5
102
0
35
0
0
0
1500
131
8.5
15.9
8.8
2.38
100
11.63
0
2.65
3.7
262
922
131
0
15.1
7.3
1.5
102
0
35
0
0
0
1500
a Inpersol 1.5%b Urea nitrogen = (Ureal >< 28/60
Dialysis Group (M-UD, N = 10) was treated as above, except
that the dialysate was formulated to contain concentrations of
urea, creatinine, calcium, phosphorus, sodium, potassium,
chloride, and bicarbonate similar to those found in the blood of
post-48 hour nephrectomized rats (Tables 1 and 2). The Phos-
phorus Dialysis Group (P-UD, N = 8) was treated as above,
except that the dialysate contained uremic (elevated) levels of
phosphate, but was otherwise identical to therapeutic dialysate.
The Sham Nephrectomized Group (Sham, N = 16) was omen-
tectomized but not nephrectomized, and these renally intact
rats were dialyzed as above, commencing 24 hours after ne-
phrectomy. As illustrated in Figure 2, daily EPD sampling,
dialysis, and overnight Q.EEG measurement was continued for
70 hours.
Regional cerebral glucose uptake
This was studied in animals of the Sham, Attrition and TD
groups. After the morning EPD sample of the fourth day, the
conscious unrestrained animals were administered a 100 tCi
pulse of 14C-2-Deoxy-D-glucose via the jugular venous catheter
and 45 minutes later sacrificed under light halothane anesthesia
by exsanguination, perfusion and fixation (100 ml 0.9% NaCI
followed by 300 ml phosphate buffered formalin, 10%, pH 7.2).
Perfused brains were harvested, fixed for five further days and
then microdissected for '4C-2DG estimation. The microdissec-
tion technique has been published elsewhere (Lipman and
Totchard, Life Science, in press).
Briefly, this was accomplished by placing the fixed brain
ventral side uppermost in a stainless steel template (Activa-
tional Systems, Inc.) and slicing coronally at 1.0 mm intervals.
The tissue slices were laid on a rubber cutting mat and 25
regions of interest extirpated by appropriately sized tissue
punches using the method of Palkovits and Brownstein, and
Paxinos and Watson [25, 26]. The wet tissue samples were
weighed, placed in polyethylene cryovials and vacuum desic-
cated over calcium carbonate for 36 hours. Dry weights were
then obtained and the tissue transferred to glass scintillation
vials for digestion under controlled rehydration (0.5 ml Proto-
sol, New England Nuclear, Boston, Massachusetts, USA; with
0.05 ml distilled water) in an orbital shaker for 18 hours.
Scintillation fluid (10 ml, Econoflor, DuPont, Wilmington, Del-
aware, USA) was then added, the vials vortexed and scintilla-
tion counting conducted for five minutes with a wide open
window.
Calculation of regional cerebral glucose uptake (rCGlu)
This was achieved by computing the entire '4C DPM/mg (wet
weight) contained by the brain as a whole and expressing each
sample DPM/mg as a fractional percentage of the whole brain
total [27, 28]. This value is thus relative and dimensionless and
expresses the fractional accumulation of tracer in each region of
interest. This technique adjusts for the large variations in the
amount of tracer found in the brains of the different animals and
also many of the problems of quantitation characteristic of
autoradiographic videodensitometry. Moreover, it has been
validated against the latter technique by Meibach et al [27].
Values of rCGlu were computed for each sample within each
brain, and the mean value obtained for each treatment to assess
the effect of each treatment relative to that of the Sham group.
Relative rCGlu (RrCGIu) values were calculated expressing
each rCGlu value as a percentage of the parallel Sham treatment
for each region of interest.
Statistics
Analysis of variance was conducted on group comparisons,
pairwise analysis being made by Student's t-test. Linear regres-
sion analysis was performed by the least squares method.
Results
Control of ECF solutes by PD
ECF solutes sampled by the method of low-volume (20 ml)
equilibrated peritoneal dialysis (EPD) were obtained before
(AM) and following (PM) the daily dialysis period on each of the
two days in which PD was conducted in this study, and again on
the morning of the third day before sacrifice, during rCGlu
estimation. Our data are shown in Figure 3. In undialyzed
attrition animals, elevated EPD levels of urea nitrogen (134
4.8 mg/dl), creatinine (2.5 0.9 mg/dl), phosphorus (13.6 4
mg/dl), calcium (5.9 1.7 mg/dl) and potassium (6.4 1.7
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Fig. 2. Protocol for the treatment of surgically prepared nephrectomized (Nx) or Sham Nx animals. Dialysis = eight 30 ml, 30 minute exchanges
conducted per day except in attrition group rats. E = equilibrated peritoneal dialysis sample obtained for solute analysis (20 ml, TD solution, 60
mm). 2DG = animals sacrificed for in vivo regional cerebral glucose uptake studies under the 2-Deoxyglucose protocol.
mEq/l) were apparent by 24 hours following nephrectomy (AM
of the following day) compared with Sham operated animals.
Abnormally elevated levels of urea N and creatinine continued
to rise slightly over time; phosphorus, calcium and potassium
remaining at approximately the same elevated level. The regi-
men of therapeutic dialysis (TD) employing therapeutic dialy-
sate (Table 2) in eight 30-minute exchanges per day appreciably
lowered the ECF solute burden as demonstrated by reduced
EPD levels of urea nitrogen (69.6 21 mg/dl), creatinine (1.9
0.5 mg/dl), phosphorus (6.8 1.7 mg/dl), calcium (5.7 1.7
mg/dl), and potassium (4.3 1.0mEq/liter) measured in the PM
sample of the first day. Overnight generation of solutes during
the time of Q.EEG measurement re-established the previously
abnormal levels by the morning of the second day, when the
solute-removing effect of TD was again demonstrated. Mock
uremic dialysate (M-UD, Table 2) was effective at preventing
dialytic extraction of the different solutes with which the
solution had been made. EPD solute levels measured in M-UD
treated animals were not significantly different from those of the
attrition group (P > 0.05), in contrast to TD treatment (P <
0.05). Phosphate added to therapeutic dialysate (P-UD, Table 2)
successfully maintained EPD phosphate levels within the range
found in both attrition and M-UD treatments (P >0.05), other
EPD-solute levels being comparable with those of the TD group
(P> 0.05).
Elect roencephalo graphic studies
Preliminary studies showed that within the twenty Hertz
frequency spectrum available to our analysis, the delta range (0
to 3 Hz) was highly susceptible to breathing artifacts. The
majority of the Q.EEG power, estimated from the compressed
spectral array of the fast Fourier transformation resides in the
rat as in man, within the ten Hertz range encompassed by theta
(3 to 7 H) and alpha (7 to 13 Hz) frequency bands which are the
components of our index, the theta:alpha ratio (TAR).
The control value (mean sEM) of the TAR was thus
calculated to be 1.57 0.29 for the entire group of rats, the
standard error being 18% of the mean. This variation is com-
pounded of both inter- and intra-animal variation and includes a
component, therefore, from each animal's circadian and infra-
dian rhythms over the measuring period (14 hours from each of
three days).
Figure 4 illustrates and Figure 5 summarizes (for the 53 to 67
hr Q.EEG measurement interval) the effect of PD treatments on
the Q.EEG. No appreciable change from control values was
noted in the TAR ratio of EEG powers measured from Sham
nephrectomized rats dialyzed using therapeutic dialysates over
either of the two Q.EEG measurement periods (P > 0.05).
Nephrectomy unrelieved by dialysis (attrition treatment) was
temporally associated with a linear increase in the TAR (P <
0.05 compared with control value). Therapeutic dialysis of
nephrectomized animals significantly (P <0.001) reduced TAR
values below those in the attrition animals to levels comparable
(P > 0.05) to those of the sham nephrectomized animals.
Dialysis of nephrectomized animals using either M-UD or P-UD
solutions (Table 2) produced comparable (P > 0.05) levels of
TAR that were intermediate between those of the attrition and
the TD treated animals (P < 0.05).
Relationship between Q.EEG and EPD-solutes
Overnight average concentrations (PM to AM) were calcu-
lated for each of the measured solutes so as to obtain a single
value representative of each solute's concentration during the
period of Q.EEG measurement. Linear least squares regression
analysis was then conducted between each animal's overnight
average TAR value and its overnight average chemistry values.
Small positive correlations were found for urea nitrogen (r =
0.37, P < 0.001); creatinine (r = 0.31, P < 0.01); and phospho-
rus (r = 0.31, P < 0.01). The correlation between TAR and
overnight average calcium concentration (r = 0.184) was not
statistically significant (P = 0.09). These correlations were
comparable with values obtained in our earlier work [19]. In the
Sham animals, a small positive correlation was found between
TAR and urea nitrogen but otherwise no relationship was
found. TD animals resembled Sham animals in that the positive
correlations associated with the attrition state were not evident.
Correlations between TAR and overnight average EPD solute
levels was largely negative in the M-UD and P-UD groups.
Regional cerebral glucose uptake studies
At the time of measurement, relative regional cerebral glu-
cose uptake (RrCG1u) values of the animals of the attrition
group differed (P < 0.05) from those of the Sham group at only
three brain sites: hippocampus, geniculate nuclei and the sub-
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sium levels remained essentially stable at the 24 hour level. As0.0 r1,' — expected, dialyzed, Sham-nephrectomized animals maintainedC AM PM AM PM AM
control levels of the measured solutes. Also, as expected, daily
Day 1 Day 2 Day 3 TD treatment tended to normalize EPD-solute concentrations
Fig. 3. Equilibrated peritoneal dialysis (EPD, 20 ml 60 mm dwell) while recurrent abnormalities overnight presumably reflected
levels of salutes sampled throughout the study. Data are shown for the solute generation. The single exception was the rise in total
attrition group (—-—); TD group (--LI--); M-UD treatment (A calcium (despite concurrent rise in phosphate), perhaps re-P-UD treatment (—A-—) and Sham dialysis (—0-—). flecting the relatively high level of dialysate calcium and possi-
bly increased parathyroid hormone secretion. M-UD treatment
generally maintained the EPD solute burden at high levels,
stantia nigra (Fig. 6). The effect of TD treatment on glucose sometimes higher than dialysate levels, presumably due toincorporation in these areas is illustrated in Figure 7. At the continued solute generation. However, the decrease in PM
geniculate bodies the depressed RrCG1u associated with unre- values on day 2 in spite of the M-UD treatment suggests thatlieved nephrectomy was attenuated by a prior history of TD (P
endogenous solute generation had slowed, perhaps reflecting
<0.05 compared with Sham); but similarly improved values at decreased solute ingestion (not measured) due to uremic ano-
the hippocampus and substantia nigra did not reach statistical rexia. As anticipated and intended, P-UD treated nephrecto-
significance. mized animals displayed an EPD solute profile comparable to
TD treated rats with the exception of EPD-phosphate levelsDiscussion
which were comparable to those of both M-UD and attrition
Control of EPD solute concentrations groups (P > 0.05).
Abnormal ECF solute burdens accumulate rapidly and inex-
orably in the totally nephrectomized rat. From Figure 3 it can Association of EPD solutes and Q.EEG
be seen that the major extent of solute elevation was achieved As shown in Figures 4 and S the chemical abnormalities in the
within the first 24 hours. Thereafter, in the attrition group, attrition state are associated with slowing of the Q.EEG back-
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ground rhythm (increased TAR). Examination of the effect of
TD treatment confirms the hypothesis that TAR increase is in
some way dialysable-solute-dependent. TD treatment amelio-
rates both the deranged EPD solute levels and increased TAR
of the attrition state. This finding is in agreement with the
clinical findings in human and animal studies [3—6, 11—14, 2 1—23,
29—43] and establishes this model as a clinically relevant bioas-
say system.
When the removal of ingredient solutes was prevented by
M-UD treatment, we nevertheless observed a partial ameliora-
tion of the increased TAR due to nephrectomy (Fig. 5). How-
ever, the encephalopathy was also not exacerbated. Clearly
therefore, some neurotoxic component of the uremic ECF was
removed or (alternatively) an indirect adaptive injury was
ameliorated by M-UD treatment; this component was not one
of the commonly measured solutes with which the M-UD
solution had been formulated. We therefore infer: (1) the
presence of some other, unmeasured, dialysable neurotoxic
substance that is removed (altered) during M-UD dialysis and
that produces the slowing effect on the Q.EEG; and (2) that one
or more of the M-UD component solutes continues or syner-
gizes with the action of this unknown uremic neurotoxin since
the TAR response is incomplete when compared with the effect
of TD. Since TD treatment itself reduced elevated TAR values
to within the Sham group range, we would suggest that the
effect of TD treatment is to reduce the levels of this hypothet-
ical neurotoxin to subtoxic concentrations within our bioassay.
Presumably M-UD treatment was equally efficacious in this
regard, yet dialysis with M-UD solutes failed to completely
suppress the neurotoxic effects. Since only weak correlations
were found between TAR and EPD solutes in the M-UD group,
this tends to rule out any direct dose-dependent role for any of
these solutes in the neurotoxic effect. On the other hand,
increasing levels of the (unknown) neurotoxin could account for
the increasing TAR as these EPD levels fell overnight during
the time of Q.EEG measurement, probably due to reduced
generation of the ingredient solute. It seems plausible to con-
clude that some component of the M-UD solution interacted
with a residual neurotoxic effect to prevent the full ameliorative
effect of dialysis (TD) on the Q.EEG. Our findings obtained
with the P-UD treatment (Fig. 5) suggest that this component
may be phosphorus, or phosphorus-induced. Phosphorus may
exert indirect neurotoxic effects via an action on parathyroid
hormone. Elevated phosphorus levels are known to stimulate
the parathyroid glands to increase PTH production. In an
anephric animal such as the present model, the normal negative
feedback effect of PTH on phosphorus excretion—stimula-
tion—cannot operate, leading presumably to enhanced PTH
levels and further enhancement of its neurotoxicity. Arieff and
Massry [54] and also Cooper, Lazarowitz and Arieff [55] have
reported—in support of this hypothesis—that abnormal EEG
patterns associated with the slowing of the EEG frequencies are
correlated with PTH elevation. PTH neurotoxicity may arise
from its ability to depress neuronal conduction velocity, an
effect most probably engendered via deranged calcium metab-
olism and increased calcium burden within the nerve, according
to the work of Mahoney and Arieff [56]. Goldstein, Chui and
Massry [571 have shown that a parathyroid extract reversibly
increases the calcium burden of dog nerve. They find, more-
over, that depression of conduction velocity is in correlation
with the nerve calcium burden.
Solutes other than phosphorus remain to be tested in our
assay by means of solute-specific dialysis. Moreover, because
generation and retention of other unmeasured solutes presum-
ably proceeded concurrently with those we measured, we are
unable to conclude that the measured solutes themselves en-
gendered the associated TAR increases.
The technical and analytic loads of these initial experiments
precluded control or examination of such further important
variables as nutritional intake (such as, by pair-feeding the
animals), dialysate protein loss, nitrogen balance, or the re-
sponses of parathyroid or other hormone secretion rates and
levels.
ECF solutes, the Q.EEG and brain glucose uptake
Having documented the production by nephrectomy and
remission by peritoneal dialysis of uremic encephalopathy in a
laboratory model employing conscious ambulatory rats, we
next began an initial exploration of possible cerebral mecha-
nisms for these effects. Since glucose is the brain's primary
energy source, we hypothesized that glucose metabolism, and
perhaps uptake might be altered in this model. Hence measure-
ments of glucose uptake by the 2-Deoxy-D-glucose (2-DG)
method 144—48] were studied in attrition, TD and Sham-nephrec-
tomy-dialyzed groups. Because variations of whole-brain up-
take between animals were anticipated, and in order to localize
cerebral metabolic effects of uremia and dialysis within the
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Fig. 6. Survey of 2DG uptake (rCGlu) in the rat brain in attrition (uremic) animals (open columns) and sham group animals (black columns).
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brain, methods for direct counting of microdissected brain
tissue were chosen [27, 28]. This choice also circumvented
problems in the usual techniques of quantifying autoradiograph-
ically detected tracer [48]. Precedents for these methods for
localization of cerebral metabolic responses to functional activ-
ity are known in such applications as olfactory stimulation [461,
peripheral nerve stimulation or visual deprivation [47], effects
of lysine vasopressin and ACTH fragments [49], the ACTH
analogs, alpha-MSH and corticosterone [48] and Naloxone [501.
The neurotoxic effects of aluminum salts have recently been
quantified by this technique (Lipman and Tolchard, Life Sci-
ence, in press).
Accordingly 20 brain areas were surveyed and the counts in
each were factored by the whole brain uptake in each animal,
Gen cu late
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FIg. 7. Group average (mean SEM) regional
cerebral glucose uptake values (RrCGIu %)
for geniculate nuclei, substantia nigra and
hippocampus of animals of the Sham,
attrition and TD. *D < 0.05.
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then aggregated, to permit comparison of the regional cerebral
glucose uptake (rCGlu) in attrition and Sham groups (Fig. 6).
While we expected rCGlu deficits in cortical sites and in the
thalamic nuclei of origin of the thalamocortical (corticofugal)
rhythm generators, no such deficits were found. The neuro-
physiological source of Q.EEG slowing in this model has thus
not been identified, either because the slowed electrical activity
does not depend upon reduced glucose uptake, or because the
method is too insensitive to detect the small magnitude of
changes in these and other brain areas.
Instead, as illustrated in Figure 6, rCGlu was reduced only in
the geniculate, substantia nigra and hippocampal areas. When
the changes are expressed as relative regional cerebral glucose
uptake (RrCG1u) as a percent of the Sham group value (Fig. 7),
the depressive effect of untreated uremia is again seen in the
attrition group. Presumably as a result of prior therapeutic
dialysis, glucose uptake in the TD group does not differ statis-
tically from that in the Sham animals, but improvement from
attrition levels reaches statistical significance only in the ge-
niculate area. The mechanistic basis for these effects remains to
be explored.
These three areas may, however, be functionally relevant to
certain functional cerebral deficits in renal failure if not to the
Q.EEG slowing. For example, the 'geniculate' tissue sampled
in these studies mainly comprised the lateral geniculate nuclei
which are the primary neural relays to the visual cortex [52]. A
similar metabolic deficit in this area in man may be the
biological basis for the deficits in the visual evoked potential
latencies observed in human renal failure [34—36, 511. The
substantia nigra, containing the dopaminergic nuclei of the
extrapyramidal nigrostriatal tract, is involved in initiation of
movement and fine motor control. Deficits here may be respon-
sible for the reduced locomotor activity as well as the tremors
typical of uremic encephalopathy in the rat as in man and other
species. Finally, the hippocampus is involved in learning and
memory, both of which are deficient in encephalopathic uremic
patients and in animal models of the condition [39—42, 53].
In conclusion, the present model provides a bioassay with
which to investigate the effects and identity of the "uremic
neurotoxin(s)" and may find utility in investigations of neuro-
pharmacological effects in the altered uremic state. Our present
data suggest that the "unknown dialysable neurotoxin" is
peritoneally permeable in this model (that is, has a molecular
weight of <15000) and is not identical with any of the commonly
measured solutes. Its toxicity is enhanced, however, by uremic
levels of one or more of these solutes for which role phosphorus
is provisionally a likely candidate.
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